Log in

NYSE:GMEDGlobus Medical Stock Price, Forecast & News

$45.57
-0.89 (-1.92 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$44.61
Now: $45.57
$46.38
50-Day Range
$45.00
MA: $50.59
$55.61
52-Week Range
$33.41
Now: $45.57
$60.15
Volume935,000 shs
Average Volume1.61 million shs
Market Capitalization$4.45 billion
P/E Ratio31.43
Dividend YieldN/A
Beta1
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers imaging, navigation, and robotic assisted surgery technology solutions, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures. In addition, it provides regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. Further, the company offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems. Additionally, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Read More
Globus Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.82 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP37957720
Phone610-930-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$785.37 million
Cash Flow$2.19 per share
Book Value$14.05 per share

Profitability

Net Income$155.21 million

Miscellaneous

Employees2,000
Market Cap$4.45 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive GMED News and Ratings via Email

Sign-up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.

Globus Medical (NYSE:GMED) Frequently Asked Questions

How has Globus Medical's stock been impacted by COVID-19 (Coronavirus)?

Globus Medical's stock was trading at $38.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GMED shares have increased by 22.1% and is now trading at $46.46. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Globus Medical?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Globus Medical.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Globus Medical.

How were Globus Medical's earnings last quarter?

Globus Medical Inc (NYSE:GMED) issued its quarterly earnings data on Thursday, May, 7th. The medical device company reported $0.29 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.38 by $0.09. The medical device company earned $190.60 million during the quarter, compared to analysts' expectations of $192.88 million. Globus Medical had a net margin of 18.66% and a return on equity of 12.21%. Globus Medical's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.36 earnings per share. View Globus Medical's earnings history.

What price target have analysts set for GMED?

10 analysts have issued 12-month price objectives for Globus Medical's shares. Their forecasts range from $50.00 to $67.00. On average, they expect Globus Medical's stock price to reach $57.00 in the next year. This suggests a possible upside of 22.7% from the stock's current price. View analysts' price targets for Globus Medical.

Has Globus Medical been receiving favorable news coverage?

Headlines about GMED stock have trended neutral recently, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Globus Medical earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave press coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Globus Medical.

Are investors shorting Globus Medical?

Globus Medical saw a increase in short interest in June. As of June 15th, there was short interest totaling 5,600,000 shares, an increase of 12.4% from the May 31st total of 4,980,000 shares. Based on an average daily trading volume, of 1,220,000 shares, the short-interest ratio is currently 4.6 days. Approximately 7.6% of the shares of the company are short sold. View Globus Medical's Current Options Chain.

Who are some of Globus Medical's key competitors?

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Walt Disney (DIS), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Netflix (NFLX), Paypal (PYPL), Advanced Micro Devices (AMD) and Intel (INTC).

Who are Globus Medical's key executives?

Globus Medical's management team includes the following people:
  • Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 52)
  • Mr. David M. Demski, CEO & Director (Age 61)
  • Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 48)
  • Mr. David D. Davidar, Co-Founder & Director (Age 53)
  • Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 54)

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.05%), Mount Yale Investment Advisors LLC (0.02%), Symphony Financial Ltd. Co. (0.01%), Compass Ion Advisors LLC (0.01%), Diversified Trust Co (0.01%) and 6 Meridian (0.00%). Company insiders that own Globus Medical stock include Anthony L Williams, David C Paul, David D Davidar, James R Tobin and Kelly Huller. View institutional ownership trends for Globus Medical.

Which major investors are selling Globus Medical stock?

GMED stock was sold by a variety of institutional investors in the last quarter, including 6 Meridian, and Compass Ion Advisors LLC. Company insiders that have sold Globus Medical company stock in the last year include David D Davidar, and Kelly Huller. View insider buying and selling activity for Globus Medical.

Which major investors are buying Globus Medical stock?

GMED stock was acquired by a variety of institutional investors in the last quarter, including Symphony Financial Ltd. Co., Diversified Trust Co, Envestnet Asset Management Inc., and Mount Yale Investment Advisors LLC. View insider buying and selling activity for Globus Medical.

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $46.46.

How big of a company is Globus Medical?

Globus Medical has a market capitalization of $4.53 billion and generates $785.37 million in revenue each year. The medical device company earns $155.21 million in net income (profit) each year or $1.68 on an earnings per share basis. Globus Medical employs 2,000 workers across the globe.

What is Globus Medical's official website?

The official website for Globus Medical is www.globusmedical.com.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.